Rapid Micro Biosystems, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 10, 2023. This is an annual report, not a standalone fourth-quarter report, and the filing text does not provide clear standalone Q4 financial results.
Business context
The company sells the Growth Direct platform, which automates microbial quality-control testing for pharmaceutical manufacturing. Revenue comes from systems, proprietary consumables, software, validation and field services, and service contracts. Consumables and service contracts provide recurring revenue once systems are installed and validated.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $17.1 million | $23.2 million |
| Product revenue | $11.1 million | $15.5 million |
| Service revenue | $6.1 million | $6.1 million |
| Recurring product and service revenue | $11.0 million | $7.8 million |
| Gross loss, before R&D and other operating expenses | $(8.5) million | $(7.7) million |
| Operating loss | $(63.2) million | $(47.2) million |
| Net loss | $(60.8) million | $(73.5) million |
| Net loss per share, basic and diluted | $(1.43) | $(3.94) |
| Cash used in operating activities | $(58.5) million | $(55.0) million |
- Recurring revenue rose 40.5% and represented 64.1% of total revenue, versus 33.7% in 2021.
- Consolidated gross margin was approximately negative 49.8%, compared with negative 33.3% in 2021; the prior year included BARDA revenue and related costs.
- At year-end, cash, cash equivalents and short- and long-term investments totaled approximately $138.4 million. Current assets were $138.6 million and current liabilities $19.1 million.
- No long-term debt was outstanding. Lease liabilities were approximately $8.0 million.
- Accumulated deficit was $375.9 million. The company reported 125 cumulative system placements and 103 cumulative validated systems.
Changes versus FY2021
- Revenue declined 26.3%, primarily because fewer Growth Direct systems were placed; product revenue fell 28.7%. The company placed 9 systems, versus 29 in 2021, while systems validated during the year fell to 19 from 33.
- Recurring revenue increased despite lower system placements, supported by a larger base of validated systems. Service revenue was nearly flat.
- Operating loss increased by $16.0 million as operating expenses rose 14.0%, including higher R&D, sales and marketing, and G&A costs.
- Net loss narrowed year over year largely because 2021 included a $19.6 million preferred-stock warrant fair-value loss and a $3.1 million debt-extinguishment loss. These prior-year items were absent in 2022.
- Cash used in operations increased by $3.6 million. Cash and cash equivalents fell substantially, while the company held more short- and long-term investments.
Outlook, commentary and risks
- Management expects a return to commercial revenue growth and continued recurring-revenue growth in 2023, but provides no numerical guidance in the supplied filing text.
- An August 2022 restructuring reduced the workforce by approximately 20%. The company recorded a $1.1 million charge and expected $8–$9 million in annualized savings by year-end 2023, with some savings reinvested in commercial execution and product development.
- The strategic-alternatives review concluded in December 2022. The board rejected an unsolicited $5-per-share cash acquisition proposal and chose to continue executing the company’s strategy.
- Management stated that available cash, cash equivalents and investments were expected to fund operating and capital needs for at least 12 months after the financial statements were issued. The estimate depends on assumptions; there is no committed external funding source, and further capital may be needed.
- Key risks include persistent losses and cash burn; uncertain customer adoption and lengthy validation and sales cycles; reliance on a small number of system sales; and customer concentration, with one customer representing 22.8% of FY2022 revenue.
- Other risks include pandemic-related customer access and supply disruptions, inflation and higher interest rates, single-source components (including a camera supplier discontinuing production), and dependence on the Lowell facility. A backup consumables manufacturing facility in Lexington was still being completed.
- Unusual items included $2.2 million of incremental G&A costs associated with the shareholder proposal and strategic review, and a $0.6 million tax benefit from a favorable German tax examination. Management reported effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Whether system placements recover and the company converts placed systems into validated, actively used systems.
- Whether recurring consumables and service revenue continues to grow enough to offset volatile system sales.
- Actual operating cash burn and liquidity runway compared with management’s at-least-12-month estimate, including any need for additional financing.
- Whether restructuring savings are realized without impairing sales, product development or customer support.
- Progress on the Lexington backup facility and qualification of an alternative camera supplier.
- Whether customer concentration and the company’s negative gross margin improve as production volumes and the installed base grow.